Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) – Equities research analysts at HC Wainwright upped their Q4 2025 earnings per share estimates for shares of Genmab A/S in a research report issued on Wednesday, January 28th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of $0.51 for the quarter, up from their prior estimate of $0.40. HC Wainwright also issued estimates for Genmab A/S’s Q4 2026 earnings at $0.46 EPS and FY2026 earnings at $1.68 EPS. Wall Street Zen upgraded Genmab A/S from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. Positive Sentiment: HC Wainwright raised FY2025 and Q4 2025 EPS estimates (FY2025 to $2.00; Q4 2025 to $0.51), which supports expectations for stronger near‑term profitability versus prior forecasts.